451: CCTA, CT-FFR, and AI Plaque Analysis to Personalize CAD Detection, Prevention, and Management with Dr. Michael Gallagher

CardioNerds Dr. Joseph Kassab, Dr. Mariana Garcia-Arango, and Dr. Christopher Mason explore the technological revolution of Coronary CT Angiography (CCTA) with expert faculty Dr. Michael Gallagher. The discussion details how CCTA has evolved into a frontline diagnostic and preventive tool, moving beyond simple anatomy to incorporate physiology via CT-FFR and biology through AI-driven plaque quantification. The episode reviews landmark evidence like the SCOT-HEART and PROMISE trials, the nuances of CAD-RADS 2.0 reporting, and the emerging role of AI in monitoring treatment response and personalizing cardiovascular care. Critically, they also discuss some of the assumptions and limitations of these techniques.

Stay tuned for a matching review article to be submitted to US Cardiology Review, the official Journal of CardioNerds.

This episode was supported by an independent medical education grant from HeartFlow. All CardioNerds education is planned, produced, and reviewed solely by CardioNerds.

Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey.

US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here.

CardioNerds Multimodality Cardiovascular Imaging PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll

Pearls

Shift in Paradigm: CCTA is no longer just an anatomic test; with some key limitations, it can provide anatomy, physiology (CT-FFR), and plaque biology (AI-CPA) in a single non-invasive scan.

The "Power of Zero" vs. Plaque: While a normal CCTA has a >95% negative predictive value, future MIs often arise from non-obstructive plaque that traditional stress tests might miss.

CAD-RADS 2.0 Utility: The addition of plaque burden modifiers (P1–P4) is a "game changer," allowing clinicians to identify high-risk patients who need aggressive lipid-lowering despite having only mild stenosis.

CT-FFR as a Virtual Stress Test: CT-FFR uses computational fluid dynamics to simulate blood flow, potentially reducing unnecessary invasive catheterizations by approximately 61% without sacrificing safety.

Seeing the Invisible: AI-based quantitative plaque analysis (QCPA) can identify "subvisual" plaque and low-attenuation (lipid-rich) components that are the primary drivers of acute coronary syndromes.

Show Notes

How has the role of CCTA changed compared to traditional functional testing?

Historically, stress testing answered "is there ischemia today?", which often reflects late-stage disease.

CCTA identifies disease across the entire spectrum, asking "is there atherosclerosis and how much plaque is present?".

Landmark evidence: SCOT-HEART showed a 41% relative risk reduction in MI at 5 years attributed to intensified preventive therapies, and PROMISE showed CCTA was better at selecting patients who truly needed invasive angiography.

Diagnostic CCTA imaging depends on the protocol, contrast timing, heart rate, heart rhythm, breathholding, scanner quality, and several patient factors (obesity, prior stents, heavy calcification, complex bypass anatomy, and motion artifact all may limit imaging). “CCTA is exceptional for the right patient, with the right scanner, and the right team.”

What are the key modifiers introduced in CAD-RADS 2.0, and why do they matter?

CAD-RADS 2.0 moved beyond stenosis severity to include plaque burden (P0 to P4), high-risk plaque (HRP) features, and the presence of ischemia based on CT-FFR.

It serves as a clinical decision support tool: a patient with mild (25-49%) stenosis but "extensive" (P4) plaque burden is considered high risk and warrants aggressive risk factor modification.

How is CT-FFR calculated, and when is it most useful in clinical practice?

CT-FFR uses resting CCTA data and computational fluid dynamics to create a 3D model of coronary flow during simulated maximal hyperemia.

It is often used for intermediate lesions (40–90% stenosis) to predict if they are ischemia-producing,